ReviewFrontiers in cardiovascular medicine2021
Residual Bioprosthetic Valve Immunogenicity: Forgotten, Not Lost.
Review in Frontiers in cardiovascular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- The molecular signature of degeneration in explanted decellularized allogeneic heart valves.Frontiers in cardiovascular medicine · 2026Article
- Bioprosthetic heart valve degeneration: new insights into structural remodeling and calcification.Frontiers in cardiovascular medicine · 2026Review
- Immunotherapy in the Context of Aortic Valve Diseases.Cardiovascular drugs and therapy · 2024Review
- Bioprosthetic Aortic Valve Degeneration After TAVR and SAVR: Incidence, Diagnosis, Predictors, and Management.Journal of cardiovascular development and disease · 2024Review
- Challenges and Opportunities in Valvular Heart Disease: From Molecular Mechanisms to the Community.Arteriosclerosis, thrombosis, and vascular biology · 2024Article
- Mechanical valve replacement for patients with rheumatic heart disease: the reality of INR control in Africa and beyond.Frontiers in cardiovascular medicine · 2024Article
- Graft rejection in paediatric congenital heart disease.Translational pediatrics · 2023Review
- Soft Biomimetic Approach for the Development of Calcinosis-Resistant Glutaraldehyde-Fixed Biomaterials for Cardiovascular Surgery.Biomimetics (Basel, Switzerland) · 2023Article
- Development and testing of a transcatheter heart valve with reduced calcification potential.Frontiers in cardiovascular medicine · 2023Article
- Fibrin deposition on bovine pericardium tissue used for bioprosthetic heart valve drives its calcification.Frontiers in cardiovascular medicine · 2023Article
- Prevention by the CXCR2 antagonist SCH527123 of the calcification of porcine heart valve cusps implanted subcutaneously in rats.Frontiers in cardiovascular medicine · 2023Article
- The hybrid crosslinking method improved the stability and anti-calcification properties of the bioprosthetic heart valves.Frontiers in bioengineering and biotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite early realization of the need to control inherent immunogenicity of bioprosthetic replacement heart valves and thereby mitigate the ensuing host response and its associated pathology, including dystrophic calcification, the problem remains unresolved to this day. Concerns over mechanical stiffness associated with prerequisite high cross-link density to effect abrogation of this response, together with the insinuated role of leaching glutaraldehyde monomer in subsequent dystrophic mineralization, have understandably introduced compromises. These have become so entrenched as a benchmark standard that residual immunogenicity of the extracellular matrix has seemingly been relegated to a very subordinate role. Instead, focus has shifted toward the removal of cellular compartment antigens renowned for their implication in the failure of vascularized organ xenotransplants. While decellularization certainly offers advantages, this review aims to refocus attention on the unresolved matter of the host response to the extracellular matrix. Furthermore, by implicating remnant immune and inflammatory processes to bioprosthetic valve pathology, including pannus overgrowth and mineralization, the validity of a preeminent focus on decellularization, in the context of inefficient antigen and possible residual microbial remnant removal, is questioned.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.